This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Roche Pacing the Field in the Biotech Race

NEW YORK (TheStreet) -- In the race for biotech supremacy you'd think my focus for this article would be on a big American company like Amgen (AMGN) or Gilead Sciences (GILD) or perchance the French pharmaceutical giant Sanofi (SNY). I'm focusing today on Swiss drug maker Roche Holding AG (RHHBY).

Roche was founded in 1896 operates in the pharmaceuticals and diagnostics businesses in Switzerland, the rest of the EU, the U.S. and other international markets.

A growing number of Roche's new products, including breast cancer medications Kadcyla and Perjeta, are in fact "biologic." The term "biologic therapies" means these complex drugs are derived from living, biological organisms.

On Oct. 14th, Roche announced its plans to invest 800 million Swiss francs (roughly $880 million) in four facilities in Germany, the U.S. and Switzerland that will increase its global production of biologic therapies, which often have higher profit margins than conventional medicines and are harder for competitors to reproduce once the biologic medication loses its patent protection. Roche is currently the undisputed leader in this field.

Biologic therapies accounted for about 85% of the nearly 27 billion Swiss francs that Roche's 10 top-selling drugs generated in revenue during 2012. Rising worldwide demand for biologic pharmaceuticals will justify the $880 million investment for biologic products already on the market and help it to develop nearly 40 new biologic therapies that Roche has in its pipeline of new drugs, according to the company.

Check out this list for an impressive product pipeline straight from the company's own website. Roche is traded OTC in the U.S., but you can also own shares indirectly through the iShares MSCI Switzerland Capped Index ETF (EWL), where Roche represents over 14% of the holdings in the ETF. Another Swiss pharmaceutical powerhouse in EWL is Novartis (NVSEF), which accounts for slightly more than 13% of the fund's holdings.

Whether you favor Roche or another big biotech company like Celgene (CELG), which discovers, develops, and commercializes therapies for cancer and immune-inflammatory diseases in the United States and Europe, the biotech race for new cures and the most advanced therapies is hotter than molten lava.

Sales of biotech and biologic products will comprise 25% of the global pharmaceutical market by 2018, according to EvaluatePharma, a research company that covers the worldwide healthcare industry. Roche is predicted to be the biggest player in the biotech and biologic therapies market, with sales are expected to rise to $35.3 billion in 2018, compared to less than $27 billion in 2012.

Roche is spending nearly $1 billion to increase production facilities, including one in its hometown of Basel. It will expand or upgrade a number of other productions plants like the one in Penzberg, Germany. The company already has two facilities in California in the biologic therapies manufacturing business.

There are a number of biotechnology companies and ETFs for investors to choose from, but it's challenging to think of any company in the world that's more focused on winning "the biotech race" than Roche. Remember, it was Roche that bought Genentech back in March 2009 for almost $47 billion. No wonder the company is the Usain Bolt of the biotech world, lapping the competition like greased lightning.

At the time of publication the author had no position in any of the stocks mentioned.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $109.49 -1.20%
FB $92.40 0.00%
GOOG $638.31 -0.63%
TSLA $226.00 -2.60%
YHOO $32.35 1.50%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs